Yahoo Finance Today’s Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs >500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco.
RDI Initiates Coverage on:
Teva Pharmaceutical Industries Ltd.
https://rdinvesting.com/news/?ticker=TEVA
Gemphire Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GEMP
Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded. The Israeli-based pharma giant announced that it will present new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The drug is under review by the FDA for the preventive treatment of migraine in adults as a monthly or quarterly injection. The company said it intends to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab. Tushar Shah, M.D., Senior Vice President, Head of Global Specialty Clinical Development at Teva commented, "Migraine remains a challenging disease with considerable unmet need, due to availability of few therapeutic innovations over the past 25 years. Teva is committed to developing novel treatments for patients with migraine headaches. We are excited to share additional data at the meeting on fremanezumab, particularly over the long-term, which is critical to patients."
Access RDI's Teva Pharmaceutical Industries Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=TEVA
Gemphire Therapeutics Inc. shares closed down a little over 5% on Thursday but soared in after-hours trading with gains of over 120%. It was yesterday that the clinical-stage biopharmaceutical company announced that it achieved the primary endpoint, reduction of TGs by gemcabene, in its Phase 2b INDIGO-1 trial in SHTG patients with baseline serum TGs >500 mg/dL. Traders were celebrating as the results support the company's rationale for developing gemcabene as a treatment for NAFLD/NASH.
Dr. Evan Stein, Director Emeritus, Metabolic & Atherosclerosis Research Center in Cincinnati, remarked, "The INDIGO-1 phase 2 study in severe hypertriglyceridemia clearly shows the 600 mg dose of gemcabene to be effective and well tolerated in this difficult to treat population. Importantly the triglyceride reduction is well supported by significant reductions in LDL-C, apoB, apoE, and apoCIII and these potentially beneficial reductions were greater in the subgroups that are even more difficult to treat, those with diabetes and already on statins."
Dr. Lee Golden, Chief Medical Officer of Gemphire stated, "In a related note, we are pleased to report that both of our ongoing NAFLD/NASH proof-of-concept trials are dosing patients and remain on track to report data in late 2018 and early 2019 as previously guided. In addition, we are using the information from our INDIGO-1 trial, particularly the dose finding results, together with the results from our previous Phase 1 and 2 clinical trials, to finalize our Phase 3 trial plans. We expect to communicate more information regarding the structure and timing of our Phase 3 program once we have completed our End of Phase 2 meeting with the FDA, which we will request following the completion of the FDA's review of the 2-year carcinogenicity study, which is currently in progress."
Access RDI's Gemphire Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GEMP
Our Actionable Research on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Gemphire Therapeutics Inc. (NASDAQ: GEMP) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
